SCHEMBL23833405

SCHEMBL23833405

COc1ncc(NC(=O)c2ccc3nccnc3c2)cc1S(=O)(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.53
SMN1; SMN2 Q16637 6/20 0.53
RAB9A P51151 4/20 0.53
NPC1 O15118 3/20 0.53
TP53 P04637 1/20 0.53
KMT2A Q03164 8/20 0.51
MEN1 O00255 7/20 0.48
HTT P42858 4/20 0.48
GAA P10253 1/20 0.47
NAMPT P43490 1/20 0.46
LMNA P02545 5/20 0.45
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 3/20 0.45
MITF O75030 1/20 0.45
MAPK1 P28482 1/20 0.45
ALPL P05186 1/20 0.45
ALOX12 P18054 1/20 0.45
IDH1 O75874 3/20 0.45
HPGD P15428 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23840608 0.90 IDH1 (0.42) MAPTSMN1; SMN2RAB9ANPC1TP53
SCHEMBL23840308 0.86 MEN1 (0.46) MAPTSMN1; SMN2RAB9AKMT2AMEN1
SCHEMBL30151099 0.85 MEN1 (0.46) MAPTSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL23833436 0.85 MEN1 (0.46) MAPTSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL30151054 0.82 SMN1; SMN2 (0.53) MAPTSMN1; SMN2RAB9ATP53KMT2A
SCHEMBL23833409 0.82 SMN1; SMN2 (0.53) MAPTSMN1; SMN2RAB9ATP53KMT2A
SCHEMBL30151063 0.79 GPR27 (0.48) MAPTSMN1; SMN2RAB9AKMT2AMEN1
SCHEMBL23833480 0.79 GPR27 (0.48) MAPTSMN1; SMN2RAB9AKMT2AMEN1
SCHEMBL23833492 0.77 KDM4E (0.59) MAPTSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL23833425 0.77 MEN1 (0.41) MAPTSMN1; SMN2RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-4121030-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF Amathus Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, PPM1D MAPT 66/4885SMN1; SMN2 428/4885RAB9A 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.